Evidence for non-specific effects of live Shingles vaccination against all-cause death and hospitalisation in older adults in England: a population-based cohort study

Klara Doherty, MBChB[1,2,3]; Natalie E.R. Beveridge, DPhil[1,3]; Laura Bonnett, PhD[4]; Valerie Decraene, PhD[1,5]; Caroline Jeffery, PhD[1]; Marc Y.R. Henrion, PhD[2,6]; Daniel Hungerford, PhD[1,7*]; Neil French, PhD FRCP[1,3*]

1. The Centre for Global Vaccine Research, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, UK
2. Liverpool School of Tropical Medicine, Pembroke Place, Liverpool UK
3. Royal Liverpool and Broadgreen University Hospitals NHS Trust, members of Liverpool Health Partners, L7 8XP, Liverpool, UK
4. Department of Health Data Science, Institute of Population Health, University of Liverpool, members of Liverpool Health Partners, Liverpool L69 3GL, UK
5. Field Services, United Kingdom Health Security Agency, Liverpool L3 1DS, UK
6. Malawi-Liverpool Wellcome Research Programme, Chichiri, Blantyre 3, Malawi
7. National Institute for Health and Care Research Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool, Liverpool L69 3GL, UK

*Joint senior authors, contributed equally

Corresponding Author: Professor Neil French, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, The Ronald Ross Building, 8 West Derby Street, Liverpool, L69 7BE

Research in context

Evidence before this study

A body of research exists demonstrating an association between live vaccines and a reduction in mortality and illness unrelated to the vaccine target. This has been termed non-specific vaccine effects for which heterologous immune programming has been proposed as a possible mechanism. To date, non-specific vaccine effects have largely been demonstrated in paediatric populations in relation to live measles, oral polio, and Bacillus Calmette–Guérin (BCG) immunisation.

Added value of this study

This is the first study to evaluate mortality and hospitalisation effects in an older adult population with live shingles immunisation. Older adults are a growing population in many settings worldwide and require cost-effective interventions to reduce morbidity and mortality. This study finds a reduction in all-cause death, all-cause hospitalisation, and infection-associated hospitalisation in over 70-year-olds in England associated with live shingles vaccine exposure. These findings were not explained by any measurable confounding effect of age, socio-economic status, comorbidity, nor health-seeking behaviour.

Implications of all the available evidence

This work and other emerging reports advocate for studies with an experimental design to provide definitive evidence of non-specific vaccine effects to guide policy makers and to evaluate the possible immune mechanisms in an older immunosenescent population. There is potential for very significant benefits relating to both use of shingles vaccine and type of vaccine that needs clarity.

E: N.French@liverpool.ac.uk | T: 0151 795 9630

Abstract:

Background: Non-specific live vaccine effects have been described in paediatric populations. We investigated whether non-specific effects are observed in older adults with live shingles (*Zostavax®*) immunisation.

Methods: A population-based cohort study was performed using primary- and secondary-care data from the Clinical Practice Research Datalink in England. Shingles vaccine eligible individuals aged 70 years and over who had received pneumococcal immunisation were included. All-cause death, all-cause hospitalisation, and infection-associated hospitalisation rates were compared between live shingles vaccinated and unvaccinated person-time using time-to-first-event Cox regression and recurrent events modelling. Live shingles vaccine exposure was included as a time-varying exposure. The models were run on an overlap-weighted pseudo-population to minimise confounding.

Findings: Between September 2013 and June 2019 314,618 participants aged 70 years and over who had received pneumococcal immunisation prior to study entry were identified, of which 55% had live shingles vaccine exposure. The overlap weighted pseudo-population consisted of 60021 lives shingles vaccine unexposed and 60245·6 exposed participants. Live shingles vaccine exposure in the overlap pseudo-population was associated with a reduction in all-cause death (hazard ratio 0·64; 95% confidence interval 0·62, 0·66), a reduction in recurrent all-cause hospitalisation (hazard ratio 0·83 (0·79, 0·87)), and a reduction in first and recurrent infection-associated hospitalisation (hazard ratio for first event 0·81 (0·79, 0·83), and for recurrent events 0.75 (0.73, 0.77)). Protective vaccine effects were observed for at least five years post-immunisation.

Interpretations: Receipt of live shingles vaccine associates with lower mortality and morbidity in older adults in England. The potential for causal linkage should be validated in robust prospective studies, with major implications for national immunisation policies.

Funding: No specific funding for this project. KD was supported by an NIHR academic clinical fellowship.

Background

The live shingles vaccine (*Zostavax®,* Merck) has been routinely offered to adults in England aged 70 years and over since 1st September 2013. It has resulted in a 64% reduction in herpes zoster disease and 81% reduction in post-herpetic neuralgia in the vaccinated population.[1] As well as disease-specific protection, live vaccines have been observed to provide wider protection from other infectious pathogens and from malignancies, which has been termed non-specific vaccine effects. In paediatric populations Bacillus Calmette–Guérin (BCG), oral polio, and measles vaccination has been associated with reduced all-cause mortality in low-income settings,[2–4] and reduced hospitalisation and illness in high-income settings.[5,6] The precise mechanisms of these observations remain unclear but may include beneficial programming of the innate immune system, as well as cross-reactivity and bystander activation of the adaptive immune system, collectively termed heterologous immune effects.[7]

Whether these non-specific live vaccine effects are observed in older adults has not been assessed. Evidence of non-specific live vaccine effects in older adults would change cost-effectiveness evaluation and have important policy implications. However, older age is associated with immunosenescence which may mean live vaccines do not have the same broad effect.[7] An association between the live shingles vaccine and protection from dementia and cardiovascular disease has been demonstrated but is considered a result of direct protection from varicella zoster virus effects, rather than a non-specific effect.[8,9]

The aging population in the UK and other settings worldwide is driving a growing demand on healthcare systems.[10] There is an urgent need to develop cost-effective interventions for older adults to alleviate this health-system burden. The only live vaccine that has been used extensively in the older adult population in the UK has been the live shingles vaccine (*Zostavax®*). As a vaccine given to control a chronic established viral infection it is somewhat different to the assessment of the measles and BCG vaccines in children but nevertheless provides an opportunity to look for health benefits beyond the immediate prevention of shingles. We have used a population-based cohort study to evaluate the effect of live shingles vaccine exposure on all-cause mortality, all-cause hospitalisation, and infection-associated hospitalisation in over 70-year-olds in England. Given the limited existing evidence on non-specific effects of vaccination in older adults, this study was conducted as an exploratory, hypothesis-generating study.

Methods

Study design and data source

We performed a retrospective cohort study of live shingles vaccination as a time-varying exposure using routinely collected healthcare data from the Clinical Practice Research Datalink (CPRD) and Health Episode Statistics (HES). CPRD is a longitudinal database of primary health-care data submitted by participating practices across the UK.[11] It contains medical records for approximately 18 million currently registered patients and is representative of the population of UK. Unless patients opt out, anonymised demographic and medical data is collected monthly and quality checked at individual and practice level to ensure validity of these data. This study uses the CPRD Aurum database generated from EMIS® electronic patient records which is anonymously linked to secondary-care data through HES and to patient- or practice-level socioeconomic data through the Index of Multiple Deprivation (IMD).[11] This study followed the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guidelines for cohort studies.[12] A completed STROBE checklist is provided in Supplementary Table 1.

Study setting

Data were collected from GP medical practices in England only, as the other regions of the UK do not have linkage between CPRD and HES data. The study period ranges from 1st September 2013 when live shingles immunisation was introduced in the UK, to 30th June 2019.

Study participants

Only those eligible for live shingles vaccination were included, specifically individuals aged 70 years and over during the study period (birth year 1933 to 1948). Participants with an immunocompromising condition which would make them ineligible for live vaccination were excluded (Supplementary Table 2 for immunocompromising conditions). To minimise the impact of inherent differences in health-seeking behaviours between vaccinated and unvaccinated populations we limited participants to those who had demonstrated engagement with the UK vaccination schedule and had been immunised with the pneumococcal polysaccharide vaccine (PPV23) which is offered from 65-years of age.[13,14] Participants were excluded if they had received the lower-dose varicella zoster vaccine (*Varivax®*) (Supplementary Table 3); if they have received multiple doses of the live shingles vaccine which might reflect data inconsistencies or an unusual patient cohort; if they had received the live shingles vaccine prior to age 70 years; or if they had received the live shingles vaccine prior to September 2013. Participants were excluded if they received Zostavax before the start of eligible follow-up, defined as 28 weeks after the date of continuous registration at their medical practice, to reduce inclusion of historical vaccination records recorded after registration (i.e., vaccination records entered retrospectively at the time of registration rather than

114 reflecting new vaccination events).[15] Participants with inconsistent or implausible events, for
115 example events occurring after death, were excluded but this occurred infrequently. Full exclusion
116 criteria are illustrated in Supplementary Figure 1.

117 Primary exposure variable: Live shingles vaccination

118 Immunisation with the live shingles vaccine and date of exposure was identified from CPRD Aurum
119 observation and drug files (Supplementary Table 4 for vaccination codes).

120 Outcome variables: All-cause death, all-cause hospitalisation, and infection-associated
121 hospitalisation

122 Death during the study period was identified from the death date recorded in CPRD patient files.
123 Hospitalisation events were identified from the HES Admitted Patient Care (APC) database which is
124 linked to CPRD data via a unique patient identifier. Infection-associated hospitalisation events were
125 identified through the International Classification of Disease and Health Related Problems Revision
126 10 (ICD-10) coding of primary and secondary discharge diagnoses held by HES using previously
127 defined infectious disease diagnoses (Supplementary Table 5).[16]

128 Confounding variables

129 Baseline variables were identified to generate a propensity score of likelihood of going on to
130 received live shingles vaccination. Participant baseline age and sex at study entry were identified
131 from CPRD. To ensure anonymity CPRD only provides year of birth so all participants were given the
132 birthday 1st July for analysis purpose. Participants' baseline comorbidity status was represented by
133 the 2011 updated version of the Charlson Comorbidity Index; a continuous scale which predicts
134 mortality in high-income settings.[17] Participants were classified at baseline as having ever smoked or
135 having never smoked as ex-smoking status cannot be accurately defined in CPRD.[18] Socioeconomic
136 status was defined by the patient-level English IMD 2015 quintile and was included in the model as
137 an ordered categorical variable. If patient-level IMD quintile was not available, then practice-level
138 IMD quintile was substituted. Influenza and pneumococcal disease are major causes of mortality and
139 hospitalisation in the study population.[19] All participants were immunised against pneumococcus
140 with PPV23 prior to study entry. A continuous baseline influenza vaccination score was calculated
141 using influenza vaccine records from the three years prior to study entry. Distinct influenza
142 vaccinations were defined as vaccine events occurring at least six months apart, to avoid duplicate
143 entries for the same vaccination being treated as separate events. The total number of distinct
144 vaccinations was divided by three to generate a score ranging from 0 to 3, with higher values
145 indicating more consistent influenza vaccination over the baseline period. Finally, a continuous
146 variable was generated to reflect participants' rate of consultation at their medical practice

147 preceding study-entry as this may affect their likelihood of receiving the live shingles vaccine, and
148 their risk of hospitalisation and death. This was generated by calculating the number of weeks in
149 which a participant had contact with their medical practice in the two years preceding the year of
150 study-entry divided by the number total number of weeks (104 weeks).[20]

151 Data collection and measurement

152 Data used in this study came from routinely collected healthcare data entered by healthcare workers
153 for healthcare provision and was not originally intended for use in research. As the data is used for
154 healthcare remuneration, missing vaccine events and hospitalisation were judged to occur rarely.
155 Misclassification of exposure may occur if an event date is entered inaccurately. Data quality checks
156 are conducted by CPRD and data cleaning was conducted by the study team. Participants were only
157 included if they met the CPRD quality standards of valid age, sex, death date, registration, and
158 clinical event dates.[11] CPRD also checks that morbidity and mortality rates generated from data
159 entered by medical practices match national and regional averages.[11] Participant-time was only
160 included during continuous registration at the same medical practice to reduce misclassification of
161 variables' event dates.[15] After CPRD quality checks and data cleaning, rates of missing or
162 misclassified data were deemed to be low in this dataset and were judged not to be associated with
163 rate of exposure nor outcomes. As such, complete-case analysis was performed apart from minor
164 modifications to two confounding variables substituting practice-level IMD for missing patient-level
165 IMD and defining smoking exposure as the dichotomous 'never smoked' or 'ever smoked' rather
166 than trying to define ex-smoker status.

167 Bias

168 Care was taken to minimise the inherent differences in healthcare-seeking and health prevention
169 behaviors between vaccinated and unvaccinated populations such as limiting analysis to individuals
170 who had previously engaged with the UK adult immunisation schedule and received pneumococcal
171 (PPV23) immunisation.[13,14] Variables to evaluate healthcare-seeking behaviours such as influenza
172 vaccine exposure and frequency of attendance at the medical practice were measured. In an older
173 adult population which includes many frail individuals, the possible association between frailty and
174 non-exposure to a live vaccine was considered and evaluated in pre-defined sensitivity analyses
175 described below. Live shingles vaccination was modelled as a time-varying exposure, such that
176 individuals contributed unvaccinated person-time prior to immunisation and vaccinated person-time
177 thereafter. This approach preserves the temporal ordering of exposure and outcome, avoids
178 immortal time bias, and improves comparability between exposed and unexposed risk sets.

179 Study size

180 All eligible participants for the defined study period were included in the analysis.

181 Statistical analysis

182 *Survival analysis with time-varying vaccine exposure*

183 The study design is summarised in Supplementary Figure 2. Survival analysis with time-varying live
184 shingles vaccine exposure was performed for each outcome to compare event rates during
185 unvaccinated and vaccinated person-time. Individuals entered the study at age 69·5 years or on 1st
186 September 2013 (whichever was later). Individuals who subsequently received live shingles
187 vaccination contributed to unvaccinated person-time from study entry until live shingles vaccination
188 and to vaccinated person-time thereafter. Time-zero for the unvaccinated group was study entry,
189 and time-zero for the vaccinated group was receipt of live shingles vaccination. A study entry of age
190 69·5 was used because CPRD only provides year of birth and all participants were given the birthday
191 1st July for analysis purpose. Censoring occurred at transfer-out date when an individual stops
192 contributing data to CPRD due to death or moving to a different medical practice; at last-collection
193 date when the medical practice stops contributing quality-assured data to CPRD; or on 30th June
194 2019 (whichever was earliest).

195 *Time-to-first event and recurrent event modelling with propensity score overlap weighting*

196 A time-to-first event Cox proportional hazards frailty model with a random intercept for participant
197 medical practice was used to compare the hazard ratio (HR) between vaccinated and unvaccinated
198 person-time for all three outcomes with participants censored when they experienced the outcome
199 event of interest. Hospitalisation outcomes which allowed for recurrent events modelling were also
200 compared using a Cox Anderson Gill frailty model in which participants re-entered the study after
201 experiencing an outcome event (Supplementary Figure 2). Proportional hazards assumptions were
202 evaluated based on inspection of survival and log-log plots constructed using split person-time for
203 the time-varying exposure, and on scaled Schoenfeld residuals which were not significantly
204 correlated over time (Supplementary Figure 3)).

205 To adjust for baseline confounding a pseudo-population was generated using propensity score
206 overlap weighting. This created an emulated trial scenario in which the risk of exposure in the
207 pseudo-population was balanced between the vaccinated and unvaccinated comparison groups. All
208 hazards reported in the main results are the average treatment/vaccine effect in this overlap-
209 weighted pseudo-population. Sensitivity analyses modelled average treatment/vaccine effect on the
210 whole population with covariate adjustment and with inverse probability weighting as well. The
211 propensity score was generated using the Generalised Boosting Method (GBM) in which a
212 participants' likelihood of receiving live shingles vaccination was calculated based on baseline

213 characteristics at study entry and evaluated by covariate balancing and common support
214 (Supplementary Figure 4).[21,22] GBM flexibly captures non-linear relationships between exposure and
215 covariates. Restricted mean survival time and mean cumulative events were compared in the Cox
216 and Cox Anderson Gill models to generate absolute measure of survival.[23,24] Analyses were
217 conducted in R (version 4.3.0).[25]

218 *Sensitivity analyses*

219 Several pre-defined sensitivity analyses were performed including: Exclusion of participants with less
220 than one year between study entry and censoring who were potentially deemed too frail for live
221 immunisation; inclusion of participants who received the live shingles vaccine prior to the PPV23
222 vaccine against UK vaccination policy to evaluate potential vaccine sequence effect; exclusion of
223 participants with an outcome event within 30 days of a varicella-zoster disease event to minimise
224 on-target vaccine effects; and exclusion of participants with an outcome event within 14 days of
225 immunisation to minimize the vaccine-associated outcome effects. Exploratory analysis of risk of
226 death and hospitalisation in participants stratified by sex, age, comorbidity, socioeconomic status,
227 smoking status, and influenza vaccine exposure were performed to assess for potential effect
228 modification and evaluate the need for interaction terms in the model.

229 *Post-hoc statistical analysis: Time-varying coefficient model of hazard ratio over follow-up time*

230 The large vaccine effect size observed led to the post-hoc decision to evaluate vaccine effect over
231 time following immunisation with the hypothesis that a vaccine effect rather than confounding
232 would be largest immediately after immunisation and attenuate to the null over time. A time-varying
233 coefficient model was used to evaluate hazard over 30-day intervals over follow-up time.[26] Time-
234 zero for unvaccinated person-time was study entry while time-zero for vaccinated person-time was
235 date of vaccination. Cubic B-splines were applied to follow-up time with yearly internal knots up to
236 five years and performed better than other spline models including quadratic splines, fewer knot
237 locations, and unspecified knot locations by Akaike's Information Criterion and visualisation plots.[27]
238 The time-varying coefficient model was run as a univariate Cox proportional hazards model and a
239 multivariate model adjusted for baseline age, sex, smoking status, socioeconomic quintile, influenza
240 vaccine exposure in three years preceding study entry, consultation rate at medical practice in two
241 years preceding entry, and updated Charlson comorbidity score. Computational limits precluded
242 propensity score weighting in the time-varying coefficient model and the random intercept for
243 participants' medical practice was removed due to convergence failure as a result of low participant
244 numbers in some medical practices.

245 **Results**

246 Baseline characteristics of the overlap-weighted pseudo-population

247 The CPRD Aurum database included 314,618 participants who had received PPV23 vaccination prior
248 to entry and who were aged 70 years and over between 1st September 2013 and 30th June 2019,
249 giving a total person-time of 1,313,185 years. A total of 174,534 (55%) received the live shingles
250 vaccine during the study period and the same proportion of individuals were vaccinated in each full
251 year of follow up apart from 2013 and 2019 when only partial year data was available
252 (Supplementary Figure 5). Participants were registered at 886 GP medical practices from all ten of
253 England's 2019 geographical regions. Shingles vaccine coverage ranged from 50% in London to 60%
254 in the East Midlands. The original study population showed differences in age and comorbidity
255 (Supplementary Table 6). As such, an overlap-weighted pseudo-population with balanced risk of
256 exposure was extracted from this original dataset and was used in this study to model risk of
257 outcome associated with live shingles vaccine exposure. Overlap weighting achieved covariate
258 balancing with standardized mean difference <0·1 for all measured covariates and moderate
259 common support with an overlap coefficient of 0·575 (Supplementary Figure 3). The overlap-
260 weighted pseudo-population consisted of 60021 live shingles vaccine unexposed and 60245·6 live
261 shingles vaccine exposed participants with a mean follow-up time of 3·48 (1·96) years and 4·50
262 (1·53) years respectively. Average time to vaccination from entry in the vaccinated population was
263 1·88 (1·59) years. Baseline characteristics of the overlap study population are illustrated in Table 1.

264 Risk of all-cause death, all-cause hospitalisation, and infection-associated hospitalisation associated
265 with live shingles vaccine exposure in the overlap-weighted pseudo-population

266 The rate of all-cause death in the overlap-weighted pseudo-population was 17·5 per 1000 person-
267 years of observation (pyo) in the live shingles vaccine exposed group compared to 23·3 per 1000 pyo
268 in the vaccine unexposed group. The hazard ratio (HR) of all-cause death following shingle vaccine
269 exposure was 0·64 (95% confidence interval (CI) 0·62, 0·66) (Table 2). The survival curves
270 demonstrate a divergence of survival within one year of study entry (Figure 1).

271 The rate of first all-cause hospitalisation in the overlap-weighted pseudo-population was 228 per
272 1000 pyo in the live shingles vaccine exposed compared to 218 per 1000 pyo in the unexposed with
273 no difference in rate of first hospitalisation detected between groups (HR 0·99 (95% CI 0·97, 1·00))
274 (Table 2, Figure 1). Recurrent events modelling demonstrated a lower risk of recurrent all-cause
275 hospitalisation in individuals with live shingles vaccine exposure (HR 0·83 (95% CI 0·79, 0·87) (Table
276 3). The rate of first infection-associated hospitalisation was 47·6 per 1000 pyo in live shingles vaccine
277 exposed compared to 52·3 per 1000 pyro in live shingles vaccine unexposed with a lower
278 instantaneous hazard rate of first infection-associated hospitalisation (HR 0·81 (95% CI 0·79, 0·83))

279 and a lower instantaneous hazard rate of recurrent infection-associated hospitalisation (HR 0·75
280 (95% CI 0·73,0·77)).

281 The absolute survival gain for time-to-first-event calculated by restricted mean survival time at three
282 years was 11·2 days (95% CI 10·5, 11·9 days) for death and 13·4 days (95% CI 12·1, 14·8 days) for
283 infection-associated hospitalisation. A comparison of mean cumulative hospitalisation events in live
284 shingles vaccine exposed and unexposed demonstrated that at three years the average cumulative
285 number of events per individual was 1·66 and 2·00 respectively, equivalent to 342 fewer all-cause
286 hospitalisations per 1000 individuals at three years (95% CI 267, 417). Live shingles vaccine exposure
287 was associated with 64 fewer infection-associated hospitalisations (cumulative mean events 0·26
288 and 0·19 in live shingles vaccine exposed and unexposed respectively (95% CI 59, 70)). The hazard
289 ratios were similar in direction and magnitude using the whole original source population with
290 inverse probability weighting or with covariate adjustment compared to the overlap-weighted
291 pseudo-population (Supplementary Tables 7-10).

292 Sensitivity analyses

293 Sensitivity analyses were modelled using Cox proportional hazards model with overlap weighting. No
294 difference in HRs were observed with exclusion of individuals with less than one year follow up;
295 inclusion of individuals with PPV23 after study entry; exclusion of individuals with an outcome within
296 14 days of live shingles vaccination; nor exclusion of individuals with an outcome within 30 days of a
297 varicella-zoster disease event (Supplementary Tables 11-14). Removal of the older catch-up
298 population, who were offered live shingles vaccination between age 71 and 79 when the vaccine
299 was first rolled out, did not alter the direction of the HR but increased the magnitude of the
300 associated protective effect (Supplementary Table 15). Stratified analysis demonstrated a stronger
301 protective effect associated with vaccine exposure in participants younger at baseline, the most
302 comorbid, the least deprived, and in males (Supplementary Tables 16-18). HR for 70- to 74-year-olds
303 against death was 0·56 (95% CI 0·54, 0·58) versus 0·72 (95% CI 0·68, 0·76) for age 75 years and over,
304 while infection-associated hospitalisation HR for 70- to 74-year-olds was 0·76 (95% CI 0·74, 0·78)
305 versus 0·88 (95% CI 0·85, 0·92) for age 75 years and over. A stronger protective effect was
306 demonstrated in the most comorbid participants against all-cause hospitalisation (HR in least
307 comorbid 1·00 (95% CI 0·98, 1·02) versus most comorbid 0·72 (95% CI 0·57, 0·91)), and infection-
308 associated hospitalisation (HR in least comorbid 0·80 (95% CI 0·78, 0·83) versus most comorbid 0·69
309 (95% CI 0·52, 0·91)) (Supplementary Tables 16-18). The least deprived observed a HR of 0·62 (95% CI
310 0·58, 0·66) against death and 0·79 (95% CI 0·75, 0·83) against infection-associated hospitalisation,
311 compared to 0·72 (95% CI 0·67, 0·78) and 0·88 (95% CI 0·84, 0·93) in the most deprived. Finally, male
312 sex associated with greater vaccine protection (HR for death 0·59 (95% CI 0·56, 0·62) compared to

313 0·67 (95% CI 0·65, 0·70) for females, and HR for infection-associated hospitalisation 0·78 (95% CI
314 0·75, 0·80) compared to 0·84 (95% CI 0·81, 0·86) in females).

315 Hazard ratio over time since vaccination (post-hoc analysis)

316 Visualisation of hazard over follow-up time using the time-varying coefficient model confirms the
317 vaccine protective effect is highest within one year of immunisation and attenuates towards the null
318 over follow-up time (Figure 2). The protective effect persisted for at least five years post-
319 immunisation (Figure 2).

320 **Discussion**

321 In this study live shingles vaccine exposure in older adults in England was associated with a 36%
322 reduction in risk of death and a 19% reduction in risk of first infection-associated hospitalisation,
323 which persisted for at least five years following immunisation. Recurrent events modelling further
324 demonstrated an instantaneous hazard rate 17% lower in the vaccinated for all-cause
325 hospitalisations, and 25% lower for infection-associated hospitalisation. No protective vaccine effect
326 was detected against first all-cause hospitalisation likely reflecting the inability to distinguish elective
327 from emergency admissions. As elective admissions substantially outnumber emergency admissions
328 in England, any vaccine effect on acute hospitalisations may have been diluted. Despite the large
329 effect estimates, the survival gains associated with live shingles vaccination were modest (11 days
330 for death and 13 days for first infection-associated hospitalisation at three years) due to high survival
331 rates at three years. However the reduction in recurrent admissions translated to more substantial
332 benefits associated with live shingles vaccination with an estimated 341 fewer all-cause hospital
333 admissions per 1000 individuals over three years, and 64 fewer infection-associated hospital
334 admissions per 1000 individuals over three years.

335 As an observational study there is major potential for confounding. Inherent differences in health-
336 seeking behaviours and risk of disease has been described between vaccinated and unvaccinated
337 populations, which can influence observed vaccine effectiveness.[13] A number of strategies were
338 adopted in this study to account for this including the use of a study population which had all
339 engaged in the UK immunisation schedule by receiving PPV23 immunisation. We also created an
340 overlap-weighted pseudo-population aimed at balancing measured baseline characteristics between
341 those who go on to receive vaccination and those who do not, to reduce the inherent differences in
342 health status and health-seeking behaviour between them. The propensity score used to create the
343 overlap pseudo-population was generated using measures of health status but also measure of
344 health-seeking behaviour such as influenza vaccine exposure. Although the average treatment effect
345 did not differ substantially in direction or magnitude in the overlap-weighted pseudo-population
346 compared to the entire population with covariate adjustment or inverse probability weighting,
347 possibly due to the selection of a population who had already engaged in the UK immunisation
348 schedule by receiving PPV23 reducing confounding effects. Influenza is a common cause of death
349 and hospitalisation in older adults but incorporating influenza vaccine exposure at baseline into the
350 propensity score generation also helps control for health-seeking behaviour. Live vaccines are not
351 recommended for immunocompromised individuals due to the risk of adverse effects from the
352 vaccine.[14] It is possible that the unvaccinated group in this study included more frail individuals.
353 While individuals with a defined and recorded immunocompromising condition were excluded from

354 this study, this may not cover individuals who were deemed too vulnerable or frail by the clinician
355 for live immunisation but who do not have a specific immunocompromising condition. Sensitivity
356 analysis removed individuals who died in the first year of follow-up and were possibly deemed too
357 frail for live shingles immunisation. This did not alter the estimate substantially. Imbalances at
358 baseline were noted for comorbidity even with overlap weighting. Stratified analysis did not
359 fundamentally alter the associations, but indicated that further studies should investigate variability
360 in vaccine effects in relation to social determinants of health and demography. A consistent vaccine
361 effect against all three outcomes was observed across two models of time-to-first-event (the Cox
362 Proportional Hazards model and the time-varying coefficient model for modelling hazard over time
363 since vaccination), and across recurrent events modelling.[26]

364 The study relied on secondary data recorded by healthcare workers for healthcare provision and was
365 not originally intended for use in research. CPRD includes internal checks to ensure validity of data
366 including valid age and date of clinical events.[11] Date of death recorded in CPRD has been found to
367 largely correspond to Office of National Statistics death records and the broad and non-specific
368 nature of the all-cause hospitalisation outcome limits the risk of misclassification of outcome.[28]
369 Study follow-up time was limited to when participants were continuously registered at the same GP
370 to limit misclassification of variables. Individuals cannot be linked across practices and although
371 historical clinical information is typically retained following practice registration, some
372 incompleteness may occur. The use of the secondary data source also has significant strengths as it
373 facilitates a large sample size from a dataset which is representative of the English population.[11]

374 This is the first study to evaluate the effect of the live shingles vaccine (*Zostavax®*) in older adults on
375 mortality and hospitalisation. The results are consistent with two recent studies estimating a
376 substantial reduction in dementia diagnosis associated with live shingles vaccination in a Welsh
377 population and a 23% reduction in cardiovascular disease in South Korea which persisted for eight
378 years following immunisation.[8,9,29] In the case of the dementia association this has also been seen
379 with the recombinant non-live vaccine which may suggest an underlying mechanism linked to
380 protection from the direct consequences of varicella zoster virus, or heterologous immune effects of
381 non-live vaccines.[9,29] The reduction in cardiovascular deaths was hypothesized as a direct effect
382 through the prevention of varicella-zoster associated cardio-vascular toxicity, however the large
383 effect size raises the possibility of a broader non-specific beneficial effect.

384 The reduction in infection-associated acute hospitalisations would be consistent with the prevailing
385 ideas on the mechanism of heterologous immune effects, namely programming of the innate and
386 adaptive immune response to provide a more protective and regulated response to

387 inflammation.[30,31] Whilst there has been extensive study of the varicella zoster targeting immune
388 response of these vaccines, immunological study of off target responses may provide an efficient
389 means of determining whether biologically supportive differences exist post live shingles vaccine.[32]

390 The findings in this study suggests that despite the impairment of the immune system associated
391 with older age, live vaccines may still elicit heterologous immune-boosting effects which protect
392 from common infectious causes of morbidity and mortality. We cannot exclude residual confounding
393 in this study and therefore doubt will remain about the effect and scale. However, the size of the
394 findings and the emergence of other evidence argues strongly for the need to understand any
395 potential effects better. This study advocates for the incorporation of robust but practical
396 experimental design into vaccine policy and vaccine implementation. For example, phased or cluster
397 randomised roll-out of new vaccines or during age de-escalation to allow robust evidence
398 generation. An immediate question is whether there is any difference between live and recombinant
399 shingles vaccine. The introduction of the two-dose inactivated recombinant Shingrix® vaccine into
400 the UK schedule from 2023 provides a low-cost natural experiment to answer this question and will
401 be immediately relevant for policy.

402 In conclusion, this study offers evidence for non-specific effects of live shingles vaccine exposure in
403 individuals aged 70-years and over. These findings should be considered when evaluating the cost-
404 effectiveness of live vaccines and shingles vaccination policy in the growing older adult population,
405 and advocates for experimental design in vaccination policy and implementation.

406 **List of Abbreviations**
407 95%CI = 95% confidence interval
408 aHR = Adjusted hazard ratio
409 BCG = Bacillus Calmette–Guérin vaccine
410 CPRD = Clinical Practice Research Datalink
411 HES = Health Episode Statistics
412 HR = Hazard ratio
413 IMD = Index of Multiple Deprivation
414 ICD-10 = International Statistical Classification of Diseases and Related Health Problems Revision 10
415 IQR = Interquartile range
416 NIHR = National Institute of Health Research
417 PPV23 = 23-valent pneumococcal polysaccharide vaccine (Pneumovax™, Merck & Co®)

Footnotes

Acknowledgements: This study is based on data from the Clinical Practice Research Datalink (CPRD). CPRD is jointly sponsored by the Medicines and Healthcare products Regulatory Agency and the National Institute for Health Research (NIHR), as part of the Department of Health and Social Care. This work uses data provided by patients and collected by the National Health Service as part of their care and support. We would like to acknowledge all the data providers and general practices that made the anonymised data available for research. This study would not have been possible without the wider CPRD team at University of Liverpool including Pieta Schofield. We are indebted to Professor Peter Smith, London School of Tropical Medicine and Hygiene for making suggestions on earlier drafts of this manuscript. The views expressed are those of the author and not necessarily those of the NIHR, the Department of Health and Social Care or Public Health England.

Contributors: NF, DH, NB, KD conceived of and designed the study. DH, KD acquired the data; KD analysed the data with support from DH, CJ, LB, MH, NF, and all authors interpreted the output; KD wrote the first draft of the report; and all authors reviewed the draft and final manuscript.

Competing interests: NF and DH have previously received research-initiated and industry-initiated research grant support from GlaxoSmithKline (GSK) Biologicals for evaluation of rotavirus vaccination in the UK. DH has also received grants from GSK, Sanofi Pasteur, and Merck & Co (Kenilworth, New Jersey, USA) for rotavirus strain surveillance. KD, NB, LB, VD, CJ have nothing to disclose.

Funding: There was no direct funding for this project. KD was funded by a National Institute for Health and Care Research (NIHR) Academic Clinical Fellowship (ACF-2017-07-004). DH was funded by a NIHR Post-doctoral Fellowship (PDF-2018-11-ST2-006). DH is affiliated to the National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at University of Liverpool in partnership with the UK Health Security Agency (UKHSA), in collaboration with University of Warwick. The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or the UK Health Security Agency.

Consent for publication: Not applicable

Ethics: The protocol for this study was submitted and approved by the CPRD Independent Scientific Advisory Committee (ISAC). CPRD obtains annual rolling ethical approval (reference number 05/MRE04/87) and no additional ethical approval was required for this project which meets ISAC requirements. The data was accessed via the University of Liverpool CPRD license agreement.

Availability of data and materials: Data from this study is not available from the authors. Study data is available through formal request from CPRD.

Data sharing statement: The datasets used in this study were extracted from CPRD following CPRD approval of the study protocol and through a data sharing agreement between University of Liverpool and CPRD. The same dataset is available from CPRD. The authors are not authorised to share the datasets and are obliged to destroy the datasets according to the data sharing agreement between University of Liverpool and CPRD.

456 **References**

457 1. Walker JL, Andrews NJ, Amirthalingam G, Forbes H, Langan SM, Thomas SL. Effectiveness of
458 herpes zoster vaccination in an older United Kingdom population. Vaccine. 2018
459 Apr;36(17):2371–7.

460 2. Aaby P, Martins CL, Garly ML, Bale C, Andersen A, Rodrigues A, et al. Non-specific effects of
461 standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised
462 controlled trial. BMJ. 2010 Nov 30;341(nov30 2):c6495–c6495.

463 3. Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, et al. Randomized Trial of BCG
464 Vaccination at Birth to Low-Birth-Weight Children: Beneficial Nonspecific Effects in the
465 Neonatal Period? The Journal of Infectious Diseases. 2011 Jul 15;204(2):245–52.

466 4. Aaby P, Rodrigues A, Biai S, Martins C, Veirum JE, Benn CS, et al. Oral polio vaccination and low
467 case fatality at the paediatric ward in Bissau, Guinea-Bissau. Vaccine. 2004 Aug 13;22(23–
468 24):3014–7.

469 5. de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (Heterologous) Protection of
470 Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis. Clin
471 Infect Dis. 2015 Jun 1;60(11):1611–9.

472 6. Sørup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps,
473 and rubella and the risk of hospital admissions for nontargeted infections. JAMA. 2014 Feb
474 26;311(8):826–35.

475 7. Goodridge HS, Ahmed SS, Curtis N, Kollmann TR, Levy O, Netea MG, et al. Harnessing the
476 beneficial heterologous effects of vaccination. Nature Reviews Immunology. 2016
477 Jun;16(6):392–400.

478 8. Lee S, Lee K, Oh J, Kim HJ, Son Y, Kim S, et al. Live zoster vaccination and cardiovascular
479 outcomes: a nationwide, South Korean study. European Heart Journal. 2025 May 5;ehaf230.

480 9. Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P. A natural experiment on the effect of
481 herpes zoster vaccination on dementia. Nature. 2025 Apr 2;1–9.

482 10. Stoye G, Warner M, Zaranko B. The past and future of UK health spending [Internet]. Institute
483 for Fiscal Studies; 2024 [cited 2025 Sep 9]. Available from: https://ifs.org.uk/publications/past-
484 and-future-uk-health-spending

485 11. Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile:
486 Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019 Dec;48(6):1740–1740g.

487 12. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the
488 reporting of observational studies in epidemiology (STROBE) statement: guidelines for
489 reporting observational studies. BMJ. 2007 Oct 20;335(7624):806–8.

490 13. Weinberg GA, Szilagyi PG. Vaccine Epidemiology: Efficacy, Effectiveness, and the Translational
491 Research Roadmap. The Journal of Infectious Diseases. 2010 Jun 1;201(11):1607–10.

492 14. UKHSA UHSA. Immunisation against infectious disease. The Green Book [Internet]. GOV.UK.
493 2021 [cited 2025 Aug 12]. Available from:

494 https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-
495 green-book

496 15. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration
497 and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol
498 Drug Saf. 2005 Jul;14(7):443–51.

499 16. Torisson G, Rosenqvist M, Melander O, Resman F. Hospitalisations with infectious disease
500 diagnoses in somatic healthcare between 1998 and 2019: A nationwide, register-based study in
501 Swedish adults. The Lancet Regional Health – Europe [Internet]. 2022 May 1 [cited 2025 Aug
502 1];16. Available from: https://www.thelancet.com/journals/lanepe/article/PIIS2666-
503 7762(22)00036-9/fulltext

504 17. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the
505 Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using
506 data from 6 countries. Am J Epidemiol. 2011 Mar 15;173(6):676–82.

507 18. Booth HP, Prevost AT, Gulliford MC. Validity of smoking prevalence estimates from primary
508 care electronic health records compared with national population survey data for England,
509 2007 to 2011. Pharmacoepidemiology and Drug Safety. 2013;22(12):1357–61.

510 19. Raleigh V. What is happening to life expectancy in England? [Internet]. The King's Fund. 2022
511 [cited 2023 Sep 12]. Available from: https://www.kingsfund.org.uk/publications/whats-
512 happening-life-expectancy-england

513 20. Inns T, Fleming KM, Iturriza-Gomara M, Hungerford D. Paediatric rotavirus vaccination, coeliac
514 disease and type 1 diabetes in children: a population-based cohort study. BMC Medicine. 2021
515 Jun 29;19(1):147.

516 21. Garrido MM, Kelley AS, Paris J, Roza K, Meier DE, Morrison RS, et al. Methods for Constructing
517 and Assessing Propensity Scores. Health Services Research. 2014;49(5):1701–20.

518 22. Olmos A, Govindasamy P. Propensity Scores: A Practical Introduction Using R. Journal of
519 MultiDisciplinary Evaluation. 2015 Oct 12;11(25):68–88.

520 23. McCaw ZR, Yin G, Wei LJ. Using the Restricted Mean Survival Time Difference as an Alternative
521 to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. Circulation. 2019 Oct
522 22;140(17):1366–8.

523 24. Dong H, Robison LL, Leisenring WM, Martin LJ, Armstrong GT, Yasui Y. Estimating the Burden of
524 Recurrent Events in the Presence of Competing Risks: The Method of Mean Cumulative Count.
525 Am J Epidemiol. 2015 Apr 1;181(7):532–40.

526 25. R Core Team. R: The R Project for Statistical Computing [Internet]. [cited 2025 Oct 23].
527 Available from: https://www.r-project.org/

528 26. Therneau T, Crowson C, Atkinson E. Using Time Dependent Covariates and Time Dependent
529 Coefficients in the Cox Model [Internet]. ResearchGate. 2024 [cited 2025 Jul 24]. Available
530 from:
531 https://www.researchgate.net/publication/265041278_Using_Time_Dependent_Covariates_a
532 nd_Time_Dependent_Coefficients_in_the_Cox_Model

533 27. Bozdogan H. Model selection and Akaike's Information Criterion (AIC): The general theory and
534 its analytical extensions. Psychometrika. 1987 Sep 1;52(3):345–70.

535 28. Gallagher AM, Dedman D, Padmanabhan S, Leufkens HGM, Vries F de. The accuracy of date of
536 death recording in the Clinical Practice Research Datalink GOLD database in England compared
537 with the Office for National Statistics death registrations. Pharmacoepidemiology and Drug
538 Safety. 2019;28(5):563–9.

539 29. Taquet M, Dercon Q, Todd JA, Harrison PJ. The recombinant shingles vaccine is associated with
540 lower risk of dementia. Nat Med. 2024 Oct;30(10):2777–81.

541 30. Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LAB, Jacobs C, et al. Long-Lasting Effects
542 of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity.
543 JIN. 2014;6(2):152–8.

544 31. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LAB, Jacobs C, Xavier RJ, et al. BCG-induced
545 trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol. 2014
546 Dec;155(2):213–9.

547 32. Sei JJ, Cox KS, Dubey SA, Antonello JM, Krah DL, Casimiro DR, et al. Effector and Central
548 Memory Poly-Functional CD4+ and CD8+ T Cells are Boosted upon ZOSTAVAX® Vaccination.
549 Frontiers in Immunology [Internet]. 2015 [cited 2023 Sep 15];6. Available from:
550 https://www.frontiersin.org/articles/10.3389/fimmu.2015.00553

551

Tables and figures: Evidence for non-specific effects of live Shingles vaccination against all-cause death and hospitalisation in older adults in England: a population-based cohort study

Table 1: Baseline characteristics of overlap-weighted pseudo-population

	Live shingles vaccine unexposed n=60021	Live shingles vaccine exposed N=60245·6
Age (mean, SD)	71.71 (3.07)	71.70 (3.07)
Male sex (n, %)	31391.4 (52.3%)	31685.2 (52.6%)
Comorbid (n, %)	37830.4 (63.0%)	37016.5 (61.4%)
Cardiovascular disease	8488 (14.1%)	7611 (12.6%)
Respiratory disease	11227.4 (18.7%)	10580 (17.6%)
Liver disease	595.8 (1.0%)	433.4 (0.7%)
Diabetes Mellitus	15116.5 (25.2%)	14446.6 (24.0%)
Solid organ malignancy	11230.8 (18.7%)	11468.1 (19.0%)
Dementia	1308.6 (2.2%)	1016.5 (1.7%)
Connective tissue disease	1142.6 (1.9%)	1165.1 (1.9%)
Peptic ulcer disease	2471.7 (4.1%)	2273 (3.8%)
Updated Charlson Index of Comorbidity* (mean, SD)	3.95 (1.28)	3.89 (1.21)
Index Multiple Deprivation quintile** (n, %)		
1	16267.7 (27.1%)	16887.3 (28.0%)
2	13780.9 (23.0%)	14305.4 (23.7%)
3	11964 (19.9%)	11931.4 (19.8%)
4	9911.8 (16.5%)	9772.4 (16.2%)
5	8096.6 (13.5%)	7349.1 (12.2%)
Geographical region (n, %)		
Northeast	2816.2 (4.7%)	2721.8 (4.5%)
Northwest	10597.8 (17.7%)	10386.2 (17.2%)
Yorkshire & The Humber	2325.8 (3.9%)	2634.5 (4.4%)
East Midlands	1365 (2.3%)	1544.1 (2.6%)
West Midlands	11134.4 (18.6%)	11400.5 (18.9%)
East of England	3694.6 (6.2%)	3895.7 (6.5%)
Southwest	8802.6 (14.7%)	8766.9 (14.6%)
South Central	7828.8 (13.0%)	7638.6 (12.7%)
London	6612.1 (11.0%)	6247.1 (10.4%)
Southeast Coast	4835.7 (8.1%)	5002.7 (8.3%)
Ever smoked (n, %)	42840 (71.4%)	42761.1 (71.0%)
Rate of attendance at doctor's practice in two years preceding study entry*** (mean, SD)	0.20 (0.13)	0.20 (0.12)
Number of influenza vaccinations per year in three years preceding study entry**** (mean, SD)	0.83 (0.32)	0.84 (0.31)
Varicella-Zoster associated disease in five years preceding study entry (n, %)	2229.9 (3.7%)	2310.7 (3.8%)

Quan et al (2011); **n=299 participants with missing index of multiple deprivation, corresponding medical practice's index of multiple deprivation was substituted; * = number of weeks in which participant attended their medical practice in two years preceding year of entry to study / total of 104 weeks; **** = number of influenza immunisation events in three years preceding study entry/ 3*
SD=standard deviation

Table 2: Rate of death and hospitalisation in the overlap-weighted pseudo-population and hazard ratio associated with shingles vaccine exposure modelled using a Cox proportional hazards model with random intercept for medical practice

	Lives shingles vaccine unexposed rate/1000pyo	Live shingles vaccine exposed rate/1000pyo	Hazard ratio (95% confidence interval)
Death #outcomes/person-time years	23·3 7486/321948	17·5 2757/157949	0·64 (0·62-0·66)
Hospitalisation #outcomes/person-time years	218 49892/228608	228 20779/91038	0·99 (0·97-1·00)
Infectious hospitalisation #outcomes/person-time years	52·3 15624/298882	47·6 6810/143029	0·81 (0·79-0·83)

5

Table 3: Rate of recurrent hospitalisation in the overlap-weighted pseudo-population and hazard ratio associated with shingles vaccine exposure modelled using a Cox Anderson Gill model with random intercept for medical practice

	Lives shingles vaccine unexposed rate/1000pyo	Live shingles vaccine exposed rate/1000pyo	Hazard ratio (95% confidence interval)
Hospitalisation #outcomes/person-time years	696 224053/321845	634 100174/157880	0·83 (0·79-0·87)
Infectious hospitalisation #outcomes/person-time years	94·8 30497/321831	82·2 12980/157879	0·75 (0·73-0·77)

6

Figure 1: Survival and hospitalisation-free survival in live shingles vaccine exposed and unexposed adults aged 70 years and over



Figure 1. Survival and hospitalisation-free survival in vaccinated and unvaccinated adults aged ≥70 years. Survival curves comparing outcomes between individuals who received the live shingles vaccine and those who were unvaccinated during follow-up. Time-zero for unvaccinated person-time was study entry and time-zero for vaccinated person-time was date of vaccination. (A) Overall survival (all-cause mortality), (B) All-cause hospitalisation-free survival, (C) Infection-associated hospitalisation–free survival. Numbers at risk at yearly intervals is provided below each panel with cumulative number of events shown in parenthesis.

18 **Figure 2: Hazard associated with live shingles vaccine exposure over follow-up time**



19
20 **Figure 2: Time-varying coefficient model of hazard associated with live shingles vaccine exposure over**
21 **follow-up time.** Hazard ratio for time-to-first event was calculated over 30-day intervals from study entry for
22 unvaccinated person-time and from date of live shingles vaccination for vaccinated person-time. Time-zero for
23 unvaccinated person-time was study entry and for vaccinated person-time was date of vaccination. Cubic B-
24 splines were applied to follow-up time with yearly internal knots. The pale blue dotted line represented hazard
25 ratio from an unadjusted Cox proportional hazards model and solid blue line represented hazard ratio from a
26 Cox proportional hazards model adjusted for baseline age, sex, smoking status, socioeconomic quintile,
27 influenza vaccine exposure in three years preceding study entry, consultation rate at medical practice in two
28 years preceding entry, and updated Charlson comorbidity score. Shaded area represents 95% confidence
29 intervals. Red solid line represents median follow-up time.